23 Nov

Fiji Kava AGM CEO Presentation

This presentation and any Materials provided (materials) have been prepared by Fiji Kava Limited (Fiji Kava) and contain gene ral information about Fiji Kava activities. By accepting the Materials and attending the Fiji Kava presentation, you agree to be bound by the below terms and co nditions. Terms and Conditions This presentation is provided for information purposes only. The information contained in this presentation is not intended t o b e relied upon as advice to investors and does not take into account the investment objectives, financial situation or needs of any particular investor . Investors should assess their own individual financial circumstances and consider talking to a financial adviser or consultant before making any investment decision. Certain statements in this presentation may constitute forward looking statements. Such statements involve known and unknown ris ks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. While all reasonable care has been taken in relation to the preparation of this presentation, none of the Company, its subsid iar ies, or their respective directors, officers, employees, contractors or agents accepts responsibility for any loss or damage resulting from the use of or relianc e o n the presentation by any person. Past performance is not indicative of future performance and no guarantee of future returns is implied or given. Some of the inf ormation in this presentation is based on unaudited financial data which may be subject to change. All values are expressed in Australian currency unless othe rwi se stated. All intellectual property, proprietary and other rights and interests in this presentation are owned by the Company. KEY HIGHLIGHTS FY21 Record annual revenue result > $1.17M achieved in FY21 An increase of >65% versus prior year continuing the growth trajectory Q4 FY21 cash receipts increased >60% versus prior quarter CAGR exceeding 150% since listing $0 $200 $400 $600 $800 $1,000 $1,200 $1,400 FY19 FY20 FY21 FY22 Q1 $ REVENUE 000’s H1 H2 KEY HIGHLIGHTS FY22 Q1 record sales of $420k (+33% vs Q4 FY21) Q1 record cash receipts of $440k (+40% vs Q4 FY21) Fiji Kava has continued to operate both in Fiji and abroad during the COVID - 19 pandemic and life and travel is returning to normal Work in Progress now for first Drinking Kava supply for Australia with first shipments of products confirmed to be feasible in December New Heat Pump Dryers and Liquification processing machinery to be installed in December - January Automation, liquid handling and increased environmental control systems upgraded by March - April Meaningful upgrades in peeling, cutting and slicing machinery will give important OH&S improvements New OH&S training systems and audits have delivered >100 days without any safety incidents! $0 $200 $400 $600 $800 $1,000 $1,200 $1,400 $1,600 $1,800 $2,000 FY19 FY20 FY21 FY22 Q1 Extracts and Powders Finished Dose Form WIP Approx. value at COGs pending stocktake SUPPLY CHAIN EXCELLENCE Chemist Warehouse to invest $1.43m AUD via a share placement Full ranging and premium positioning across global network in Australia, New Zealand and Ireland. New distribution and marketing opportunities for products to launch on Chemist Warehouse's Alibaba Tmall Global store in China Chemist Warehouse to provide sales and marketing services and support NPD launches As a platinum supplier Fiji Kava receives marketing and promotional benefits, including; In store promotions and off shelf activities, catalogue advertising each month, Television advertising (Healthy Break) at significant discounts. Chemist Warehouse were issued Fiji Kava shares issued at 11c per share GROWING AVAILABILITY OF OUR PRODUCTS 50g format to be on shelf in January GROWING AVAILABILITY OF OUR PRODUCTS GROWING AVAILABILITY OF OUR PRODUCTS USA appointment of Network Nutrition part of the 10b Euro IMCD Group - with a minimum value of US$3m Australian Specialty Ingredient market continuing to grow strongly with customers including Blackmores / Bioceuticals Caruso's Microgenics Wagners BJP Pharmaceuticals INNOVATION & PRODUCT DEVELOPMENT KEY HIGHLIGHTS Targeted promotional & display activities with retailers to showcase and build the brand awareness Social media audience continues to grow across targeted social media platforms Shopify powered website online in Australia to facilitate e - Commerce integration Official kava supplier to Fiji Rugby Union, who use our kava products for recovery Naming rights sponsorship of the FijiKava Kaiviti Silktails , led by Petero Civoniceva Based on excellent Australian retail distribution Fiji Kava is now investing in mainstream advertising The announcement of the Drinking Kava Pilot Import Program allows us expand our advertising efforts to engage consumers of drinking kava in addition to OTC consumers PROMOTE THE MEDICINAL BENEFITS OF OUR PRODUCTS KEY DATA Consumer health spending globally in 2020 is estimated at over $270B with growth forecast at 2.1% YOY to 2025 2 USD $115 billion Global Vitamin and Dietary Supplement sales in 2020 3 Global Vitamin and Dietary Supplement forecast to grow 5.3% CAGR 2020 - 2025 3 The effects of Stress and General Anxiety affects at least 60% of the population in most countries 3 Over half of Australians experience one of the ‘Sleep’, ‘Mind’ or ‘Body’ pillar need - states once per week or higher 4 Global Kava Extract market expected to reach USD $774.6m by the end of 2030 Global CBD Market valued at USD $2.8b and growing at 21% per annum 1 Transparency Market Research : Kava Root Extract Market Global Industry Analysis 2020 2 Euromonitor Consumer Health in World Analysis Nov 2020 3 Euromonitor The Health of the Vitamin Industry 4 Fiji Kava Pillars and Demographics Research Project Nov 2020 5 Cannabidiol Market Size, Share & Trends Analysis Report. Grand View Research. Author and date DANODAN UPDATE Our products are all about reducing anxiety, relaxation and better sleep. Dan Stoops, Founder, Danodan “ • Financial Due Diligence Nearing Completion • Acquisition of the Danodan Hempworks LLC now contemplated, to enable: • Banking transition which is of critical importance • US Federal Govt. Loan adopted – reducing cash requirements • Smooth transition for key Danodan Staff • Sales on 1 st January 2022! Author and date DANODAN UPDATE ~1x Revenue multiple < US$500k cash utilised “ • Immediate speciality retail cross selling opportunities for FijiKava & Danodan Products • Complementary customer targets in Direct to Consumer • Revenue Impact for USA Operations • Monthly sales tracking at ~30k + USD • Sales in 2020 Full Year – US$407,629.68 • Sales in 2019 Full Year – US $552,155.77 • Patented liquid dispersible, full spectrum extraction technology to be trailed on Kava and Kava + CBD combination products for beverage
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Fiji Kava Limited (ASX:FIJ) when you join Listcorp.